Temozolomide Capsules 100 Mg – Generic Temodar (Chemotherapy Agent)

Temozolomide Capsules 100 Mg (Generic Temodar) is an oral alkylating antineoplastic agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme (concomitantly with radiotherapy and then as maintenance therapy) and refractory anaplastic astrocytoma. It readily crosses the blood-brain barrier to methylate cellular DNA and inhibit malignant tumor growth.

What Is Temozolomide 100 Mg (Generic Temodar)?

Temozolomide 100 Mg is an oral antineoplastic chemotherapy medication belonging to the imidazotetrazine class. It serves as a generic equivalent to Temodar, providing identical bioequivalence, active pharmaceutical potency, and therapeutic indications.

Unlike many conventional cytotoxic chemotherapy agents, temozolomide possesses unique biochemical properties that allow high oral bioavailability and efficient penetration through the blood-brain barrier directly into central nervous system (CNS) tissues and cerebrospinal fluid.

Temozolomide is indicated as a foundational therapy for primary high-grade malignant brain tumors under the continuous management and monitoring of an experienced clinical oncologist.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

How Does Temozolomide 100 Mg Work?

Temozolomide is an inactive prodrug that does not require hepatic metabolic activation. At physiological pH throughout the body, it undergoes spontaneous non-enzymatic chemical conversion to its active cytotoxic metabolite, MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide).

The cytotoxicity of MTIC is primarily mediated through alkylation (methylation) of DNA at the O6 and N7 positions of guanine. O6-methylguanine adducts lead to repetitive, aberrant DNA mismatch repair cycles, ultimately inducing double-stranded DNA breaks and triggering programmed apoptotic cell death in rapidly dividing tumor cells.

Patients whose tumors demonstrate promoter methylation of the DNA repair enzyme MGMT (O6-methylguanine-DNA methyltransferase) typically exhibit enhanced sensitivity to temozolomide therapy because the tumor’s ability to repair alkylation damage is diminished.

What Is Temozolomide 100 Mg Used For?

Temozolomide 100 Mg capsules are clinically indicated for the management of specific malignant brain neoplasms:

• Newly Diagnosed Glioblastoma Multiforme (GBM): Administered concomitantly with focal radiotherapy, followed by maintenance monotherapy cycles.
• Refractory Anaplastic Astrocytoma: Indicated for adult patients who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine.
• Off-label Oncologic Applications: Utilized in clinical oncology protocols for advanced neuroendocrine tumors, melanoma CNS metastases, or recurrent oligodendrogliomas under specialist guidance.

Temozolomide must be administered according to precise protocol-driven cycles determined by body surface area (BSA) and monitored with routine hematologic profiles.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Product Availability & Information

Temozolomide 100 Mg capsules are supplied in specialized child-resistant packaging to ensure exact dosing during cyclic oncology regimens. Review complete product specifications and therapeutic details:

Temozolomide Capsules 100 Mg – Generic Temodar

Temozolomide 100 Mg Dosage and Administration

Dosage is individualized based on calculated Body Surface Area ($mg/m^2$), specific treatment phase (concomitant vs. maintenance), and baseline hematologic parameters:

• Newly Diagnosed GBM (Concomitant Phase): $75\text{ mg/m}^2$ orally once daily for 42 consecutive days concomitant with focal radiotherapy, followed by a 4-week recovery period.
• Maintenance Phase (GBM): Cycle 1 begins at $150\text{ mg/m}^2$ once daily for 5 consecutive days of a 28-day cycle, potentially escalating to $200\text{ mg/m}^2$/day for 5 days in subsequent cycles if hematologic toxicity permits.
• Refractory Anaplastic Astrocytoma: Initial dose of $150\text{ mg/m}^2$ daily for 5 consecutive days of a 28-day cycle ($200\text{ mg/m}^2$ if previously untreated with intensive chemotherapy).

Capsules must be swallowed whole with a glass of water on an empty stomach (at least 1 hour before or 2 hours after meals) or at bedtime to reduce severe nausea and vomiting.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Standard Dosing Phases for Glioblastoma Multiforme

Temozolomide treatment for newly diagnosed glioblastoma follows a defined two-phase protocol:

Dose adjustments, cycle interruptions, or permanent discontinuation are guided by absolute neutrophil count (ANC) and platelet count nadirs measured prior to each cycle.

Who Should Not Take Temozolomide 100 Mg?

Temozolomide is contraindicated in patients with severe hypersensitivity reactions or specific severe physiological conditions:

• History of hypersensitivity or anaphylaxis to temozolomide or dacarbazine (DTIC), as both drugs share a common active metabolite (MTIC)
• Severe, unmanageable myelosuppression (severe neutropenia or severe thrombocytopenia prior to treatment initiation)
• Pregnancy and breastfeeding (Temozolomide is genotoxic, teratogenic, and embryotoxic; effective contraception is mandatory for females and males of reproductive potential)
• Severe hepatic or severe renal impairment where clinical stability cannot be maintained

Complete blood counts (CBCs) must show adequate bone marrow function (typically $\text{ANC} \ge 1.5 \times 10^9/\text{L}$ and platelets $\ge 100 \times 10^9/\text{L}$) before starting or continuing maintenance cycles.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Possible Side Effects of Temozolomide 100 Mg

Because temozolomide targets rapidly replicating cells, it carries cytotoxic adverse effects requiring proactive clinical management:

• Myelosuppression: Thrombocytopenia (low platelets) and neutropenia (low white blood cells) are dose-limiting toxicities, typically peaking around Day 21 to 28 of a cycle.
• Gastrointestinal effects: Moderate-to-severe nausea, vomiting, constipation, diarrhea, anorexia, and abdominal pain (antiemetic prophylaxis is standard).
• Neurological symptoms: Fatigue, headache, convulsions, hemiparesis, dizziness, or peripheral edema.
• Infectious risks: Increased susceptibility to opportunistic infections, including Pneumocystis jirovecii pneumonia (PCP) and reactivation of viral infections (such as Hepatitis B).
• Hepatotoxicity: Elevated liver enzymes (ALT, AST, bilirubin) and rare reports of fatal hepatic injury.

Patients must immediately report unexplained bruising, bleeding, fever, signs of infection, jaundice, or dark urine to their oncology care team.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Temozolomide 100 Mg Drug Interactions

Disclose all concurrent prescription medications, anticonvulsants, over-the-counter drugs, and supplements prior to taking temozolomide:

Valproic Acid: Co-administration of valproic acid reduces temozolomide clearance by approximately 5%, leading to slightly increased systemic exposure and requiring vigilance for increased toxicity.

Live Vaccines: Live or live-attenuated vaccines must not be administered during temozolomide therapy due to immunosuppression, which increases the risk of severe vaccine-derived infections.

Other Myelosuppressive Agents: Concomitant administration with other cytotoxic or myelosuppressive medications increases the severity and duration of bone marrow suppression.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Hematologic & Hepatic Monitoring Requirements

Because temozolomide causes profound myelosuppression and potential hepatic dysfunction, strict laboratory monitoring is mandatory throughout therapy:

Complete Blood Counts (CBC): During the concomitant 42-day phase, CBCs must be performed weekly. During maintenance cycles, CBCs are performed on Day 22 (expected nadir) and Day 28 (prior to initiating the next cycle).

Liver Function Tests (LFTs): Baseline liver function tests should be obtained prior to initiation and repeated midway through cycles. If significant hepatic enzyme elevations develop, dosage adjustment or permanent cessation is warranted.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Supportive Care & Infection Prophylaxis

Standard oncology protocols require specific supportive co-medications alongside temozolomide administration:

Antiemetic Therapy: Nausea and vomiting are common. Premedication with 5-HT3 receptor antagonists (such as ondansetron or granisetron) is strongly recommended prior to initial doses and during concomitant radiotherapy phases.

PCP Prophylaxis: Prophylaxis against Pneumocystis jirovecii pneumonia (using trimethoprim-sulfamethoxazole or appropriate alternatives) is required for all patients during the 42-day concomitant radiotherapy phase and continued until recovery from lymphopenia.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Official Medical Reference

For authoritative oncologic prescribing guidelines, dose calculation charts, safety profiles, and clinical trial results, refer to the official FDA DailyMed monograph:

DailyMed – Temozolomide Capsules Prescribing Information

Frequently Asked Questions About Temozolomide 100 Mg

Medical Disclaimer

This product overview is provided strictly for educational and informational purposes. Temozolomide (Generic Temodar) is a potent cytotoxic antineoplastic medication that must only be prescribed, calculated, and administered under the supervision of a specialized medical oncologist experienced in neuro-oncology chemotherapy protocols. This content does not substitute for individualized clinical advice, laboratory assessment, or specialized oncologic treatment plans.